Formulation of anti-miR-21 and 4-hydroxytamoxifen co-loaded biodegradable polymer nanoparticles and their antiproliferative effect on breast cancer cells

Molecular Pharmaceutics

Volumn 12, Issue 6, 2015, Pages 2080-2092

  Devulapally, Rammohan ^a   Sekar, Thillai V ^a   Paulmurugan, Ramasamy ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

4 hydroxytamoxifen (4 OHT); anti miRs; breast cancer therapy; estrogen receptor; microRNA 21; PLGA; polymer nanoparticles

Indexed keywords

AFIMOXIFENE; ANTI MICRORNA 21 PLUS 4 HYDROXYTAMOXIFEN; ANTINEOPLASTIC AGENT; COPOLYMER; MICRORNA 21; NANOPARTICLE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ESTROGEN RECEPTOR; TAMOXIFEN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BIODEGRADABILITY; BIOLOGICAL ACTIVITY; BREAST CANCER; BREAST CARCINOMA; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG RESISTANCE; EMULSION; GROWTH RATE; HUMAN; HUMAN CELL; NANOENCAPSULATION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; ANALOGS AND DERIVATIVES; BREAST TUMOR; CHEMISTRY; DRUG EFFECTS; FEMALE; MCF-7 CELL LINE; METABOLISM; PARTICLE SIZE; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; MCF-7 CELLS; NANOPARTICLES; PARTICLE SIZE; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 84930625441     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500852s     Document Type: Article

References (49)

1. Kamangar, F.; Dores, G. M.; Anderson, W. F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world J. Clin. Oncol. 2006, 24, 2137-50
2. Rozhkova, E. A.; Zhi, F.; Dong, H.; Jia, X.; Guo, W.; Lu, H.; Yang, Y.; Ju, H.; Zhang, X.; Hu, Y. Functionalized graphene oxide mediated adriamycin delivery and miR-21 gene silencing to overcome tumor multidrug resistance in vitro PLoS One 2013, 8, e60034
3. Soma, C. E.; Dubernet, C.; Bentolila, D.; Benita, S.; Couvreur, P. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles Biomaterials 2000, 21, 1-7
4. Greco, F.; Vicent, M. J. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines Adv. Drug Delivery Rev. 2009, 61, 1203-13
5. Sun, T. M.; Du, J. Z.; Yao, Y. D.; Mao, C. Q.; Dou, S.; Huang, S. Y.; Zhang, P. Z.; Leong, K. W.; Song, E. W.; Wang, J. Simultaneous delivery of siRNA and paclitaxel via a "two-in-one" micelleplex promotes synergistic tumor suppression ACS Nano 2011, 5, 1483-94
6. Xiong, X. B.; Lavasanifar, A. Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin ACS Nano 2011, 5, 5202-13
7. Tan, B.; Piwnica-Worms, D.; Ratner, L. Multidrug resistance transporters and modulation Curr. Opin. Oncol. 2000, 12, 450-8
8. Lee, C. H. Reversing agents for ATP-binding cassette drug transporters Methods Mol. Biol. 2010, 596, 325-40
9. Devulapally, R.; Paulmurugan, R. Polymer nanoparticles for drug and small silencing RNA delivery to treat cancers of different phenotypes Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol. 2014, 6, 40-60
10. Desta, Z.; Ward, B. A.; Soukhova, N. V.; Flockhart, D. A. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6 J. Pharmacol. Exp. Ther. 2004, 310, 1062-75
11. Hoskins, J. M.; Carey, L. A.; McLeod, H. L. CYP2D6 and tamoxifen: DNA matters in breast cancer Nat. Rev. Cancer 2009, 9, 576-86
12. Johnston, S. R. New strategies in estrogen receptor-positive breast cancer Clin. Cancer Res. 2010, 16, 1979-87
13. Koshida, S.; Narita, T.; Kato, H.; Yoshida, S.; Taga, T.; Ohta, S.; Takeuchi, Y. Estrogen receptor expression and estrogen receptor-independent cytotoxic effects of tamoxifen on malignant rhabdoid tumor cells in vitro Jpn. J. Cancer Res. 2002, 93, 1351-7
14. Coezy, E.; Borgna, J. L.; Rochefort, H. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth Cancer Res. 1982, 42, 317-23
15. Vignon, F.; Bouton, M. M.; Rochefort, H. Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogens Biochem. Biophys. Res. Commun. 1987, 146, 1502-8
16. Reddel, R. R.; Murphy, L. C.; Sutherland, R. L. Effects of biologically active metabolites of tamoxifen on the proliferation kinetics of MCF-7 human breast cancer cells in vitro Cancer Res. 1983, 43, 4618-24
17. Malet, C.; Gompel, A.; Spritzer, P.; Bricout, N.; Yaneva, H.; Mowszowicz, I.; Kuttenn, F.; Mauvais-Jarvis, P. Tamoxifen and hydroxytamoxifen isomers versus estradiol effects on normal human breast cells in culture Cancer Res. 1988, 48, 7193-9
18. Murphy, C. S.; Langan-Fahey, S. M.; McCague, R.; Jordan, V. C. Structure-function relationships of hydroxylated metabolites of tamoxifen that control the proliferation of estrogen-responsive T47D breast cancer cells in vitro Mol. Pharmacol. 1990, 38, 737-43
19. Furr, B. J.; Jordan, V. C. The pharmacology and clinical uses of tamoxifen Pharmacol. Ther. 1984, 25, 127-205
20. Fisher, B.; Costantino, J. P.; Wickerham, D. L.; Redmond, C. K.; Kavanah, M.; Cronin, W. M.; Vogel, V.; Robidoux, A.; Dimitrov, N.; Atkins, J.; Daly, M.; Wieand, S.; Tan-Chiu, E.; Ford, L.; Wolmark, N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J. Natl. Cancer Inst. 1998, 90, 1371-88
21. Taylor, C. M.; Blanchard, B.; Zava, D. T. Estrogen receptor-mediated and cytotoxic effects of the antiestrogens tamoxifen and 4-hydroxytamoxifen Cancer Res. 1984, 44, 1409-14
22. Fisher, B.; Dignam, J.; Wolmark, N.; Wickerham, D. L.; Fisher, E. R.; Mamounas, E.; Smith, R.; Begovic, M.; Dimitrov, N. V.; Margolese, R. G.; Kardinal, C. G.; Kavanah, M. T.; Fehrenbacher, L.; Oishi, R. H. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial Lancet 1999, 353, 1993-2000
23. Rouanet, P.; Linares-Cruz, G.; Dravet, F.; Poujol, S.; Gourgou, S.; Simony-Lafontaine, J.; Grenier, J.; Kramar, A.; Girault, J.; Le Nestour, E.; Maudelonde, T. Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen J. Clin. Oncol. 2005, 23, 2980-7
24. Mauvais-Javis, P.; Baudot, N.; Castaigne, D.; Banzet, P.; Kuttenn, F. trans-4-Hydroxytamoxifen concentration and metabolism after local percutaneous administration to human breast Cancer Res. 1986, 46, 1521-5
25. Si, M. L.; Zhu, S.; Wu, H.; Lu, Z.; Wu, F.; Mo, Y. Y. miR-21-mediated tumor growth Oncogene 2007, 26, 2799-803
26. Yan, L. X.; Huang, X. F.; Shao, Q.; Huang, M. Y.; Deng, L.; Wu, Q. L.; Zeng, Y. X.; Shao, J. Y. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis RNA 2008, 14, 2348-60
27. Yan, L. X.; Wu, Q. N.; Zhang, Y.; Li, Y. Y.; Liao, D. Z.; Hou, J. H.; Fu, J.; Zeng, M. S.; Yun, J. P.; Wu, Q. L.; Zeng, Y. X.; Shao, J. Y. Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth Breast Cancer Res. 2011, 13, R2
28. Devulapally, R.; Sekar, T. V.; Paulmurugan, R. Anti-proliferative effect of 4-hydroxytamoxifen loaded PLGA-b-PEG nanoparticles in human breast cancer cell lines expressing different levels of Her2 receptor World Mol. Imaging Congr. 2013, 476
29. Pecot, C. V.; Calin, G. A.; Coleman, R. L.; Lopez-Berestein, G.; Sood, A. K. RNA interference in the clinic: challenges and future directions Nat. Rev. Cancer 2011, 11, 59-67
30. Mitchell, P. S.; Parkin, R. K.; Kroh, E. M.; Fritz, B. R.; Wyman, S. K.; Pogosova-Agadjanyan, E. L.; Peterson, A.; Noteboom, J.; OBriant, K. C.; Allen, A.; Lin, D. W.; Urban, N.; Drescher, C. W.; Knudsen, B. S.; Stirewalt, D. L.; Gentleman, R.; Vessella, R. L.; Nelson, P. S.; Martin, D. B.; Tewari, M. Circulating microRNAs as stable blood-based markers for cancer detection Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 10513-8
31. Trotta, F.; Dianzani, C.; Caldera, F.; Mognetti, B.; Cavalli, R. The application of nanosponges to cancer drug delivery Expert Opin. Drug Delivery 2014, 11, 931-41
32. Urbinati, G.; Marsaud, V.; Renoir, J. M.; Sola, B. 4-Hydroxy-tamoxifen-loaded liposomes have potent anti-myeloma activity Leuk. Lymphoma 2013, 54, 1808-10
33. Urbinati, G.; Audisio, D.; Marsaud, V.; Plassat, V.; Arpicco, S.; Sola, B.; Fattal, E.; Renoir, J.-M. Therapeutic potential of new 4-hydroxy-tamoxifen-loaded pH-gradient liposomes in a multiple myeloma experimental model Pharm. Res. 2009, 27, 327-39
34. Agudelo, D.; Sanyakamdhorn, S.; Nafisi, S.; Tajmir-Riahi, H. A. Transporting antitumor drug tamoxifen and its metabolites, 4-hydroxytamoxifen and endoxifen by chitosan nanoparticles PLoS One 2013, 8, e60250
35. Escobar Ivirico, J. L.; Beaumont, M.; Garcia Cruz, D. M.; Gomez-Pinedo, U. A.; Pradas, M. M. Cytotoxic effect of 4-hydroxytamoxifen conjugate material on human Schwann cells: Synthesis and characterization J. Bioact. Compat. Polym. 2013, 28, 574-89
36. Chen, M.; Pierstorff, E. D.; Lam, R.; Li, S. Y.; Huang, H.; Osawa, E.; Ho, D. Nanodiamond-mediated delivery of water-insoluble therapeutics ACS Nano 2009, 3, 2016-22
37. Ren, Y.; Kang, C. S.; Yuan, X. B.; Zhou, X.; Xu, P.; Han, L.; Wang, G. X.; Jia, Z.; Zhong, Y.; Yu, S.; Sheng, J.; Pu, P. Y. Co-delivery of as-miR-21 and 5-FU by poly(amidoamine) dendrimer attenuates human glioma cell growth in vitro J. Biomater. Sci., Polym. Ed. 2010, 21, 303-14
38. Costa, P. M.; Cardoso, A. L.; Mendonça, L. S.; Serani, A.; Custódia, C.; Conceiçao, M.; Simoes, S.; Moreira, J. N.; Pereira de Almeida, L.; Pedroso de Lima, M. C. Tumor-targeted chlorotoxin-coupled nanoparticles for nucleic acid delivery to glioblastoma cells: a promising system for glioblastoma treatment Mol. Ther. - Nucleic Acids 2013, 2, e100
39. Danhier, F.; Ansorena, E.; Silva, J. M.; Coco, R.; Le Breton, A.; Preat, V. PLGA-based nanoparticles: an overview of biomedical applications J. Controlled Release 2012, 161, 505-22
40. Locatelli, E.; Comes Franchini, M. Biodegradable PLGA-b-PEG polymeric nanoparticles: synthesis, properties, and nanomedical applications as drug delivery system J. Nanopart. Res. 2012, 14, 1316
41. Devulapally, R.; Sekar, N. M.; Sekar, T. V.; Foygel, K.; Massoud, T. F.; Willmann, J. K.; Paulmurugan, R. Polymer nanoparticles mediated codelivery of antimiR-10b and antimiR-21 for achieving triple negative breast cancer therapy ACS Nano 2015, 9, 2290-302
42. Wang, T. Y.; Choe, J. W.; Pu, K.; Devulapally, R.; Bachawal, S.; Machtaler, S.; Chowdhury, S. M.; Luong, R.; Tian, L.; Khuri-Yakub, B.; Rao, J.; Paulmurugan, R.; Willmann, J. K. Ultrasound-guided delivery of microRNA loaded nanoparticles into cancer J. Controlled Release 2015, 203C, 99-108
43. Wang, T.-Y.; Choe, J. W.; Machtaler, S.; Devulapally, R.; Khuri-Yakub, P. T.; Paulmurugan, R.; Willmann, J. K. Effects of ultrasound parameters on cavitation-assisted delivery of PLGA-PEG nanoparticles into tumors: phantom study and preliminary in vivo results, Radiological Society of North America 2013 Scientific Assembly and Annual Meeting, Chicago, IL, December 1-6, 2013; SSA21-08.
44. Wang, T. Y.; C, J. W.; Machtaler, S.; Devulapally, R.; Khuri-Yakub, B.; Paulmurugan, R.; Willmann, J. K. Optimizing acoustic cavitation for ultrasound-microbubble-mediated delivery of PLGA nanoparticles into tumors:phantom study and preliminary in vivo results World Mol. Imaging Congr. 2013, 259
45. Woodrow, K. A.; Cu, Y.; Booth, C. J.; Saucier-Sawyer, J. K.; Wood, M. J.; Saltzman, W. M. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA Nat. Mater. 2009, 8, 526-33
46. Paulmurugan, R.; Sekar, N. M.; Sekar, T. V. Biodegradable polymer nanocarriers for therapeutic antisense microRNA delivery in living animals Proc. SPIE 2012, 8232, 823208
47. Makadia, H. K.; Siegel, S. J. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier Polymers (Basel, Switz.) 2011, 3, 1377-1397
48. Abdelwahed, W.; Degobert, G.; Stainmesse, S.; Fessi, H. Freeze-drying of nanoparticles: formulation, process and storage considerations Adv. Drug Delivery Rev. 2006, 58, 1688-713
49. Paulmurugan, R.; Tamrazi, A.; Katzenellenbogen, J. A.; Katzenellenbogen, B. S.; Gambhir, S. S. A human estrogen receptor (ER)alpha mutation with differential responsiveness to nonsteroidal ligands: novel approaches for studying mechanism of ER action Mol. Endocrinol. 2008, 22, 1552-64